S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
U.S. Military Defense Fails Without Vanadium? (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
The Battery Metal Nobody Told You About (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
The Battery Metal Nobody Told You About (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
U.S. Military Defense Fails Without Vanadium? (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
The Battery Metal Nobody Told You About (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
The Battery Metal Nobody Told You About (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
U.S. Military Defense Fails Without Vanadium? (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
The Battery Metal Nobody Told You About (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
The Battery Metal Nobody Told You About (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
U.S. Military Defense Fails Without Vanadium? (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
The Battery Metal Nobody Told You About (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
The Battery Metal Nobody Told You About (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak

Cabaletta Bio (CABA) Stock Price, News & Analysis

$16.23
+0.24 (+1.50%)
(As of 12/8/2023 08:56 PM ET)
Compare
Today's Range
$15.35
$16.56
50-Day Range
$12.22
$18.70
52-Week Range
$5.11
$19.34
Volume
983,100 shs
Average Volume
662,693 shs
Market Capitalization
$695.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.64

Cabaletta Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
70.3% Upside
$27.64 Price Target
Short Interest
Healthy
11.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.23mentions of Cabaletta Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$340,230 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.59) to ($1.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

183rd out of 942 stocks

Biological Products, Except Diagnostic Industry

31st out of 157 stocks


CABA stock logo

About Cabaletta Bio Stock (NASDAQ:CABA)

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Stock Price History

CABA Stock News Headlines

Buy Cabaletta Bio's Promising SLE Treatment
Cabaletta Bio (NASDAQ:CABA) Shares Gap Down to $16.05
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Cabaletta Bio, Inc. (CABA)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Cabaletta Bio: Q3 Earnings Insights
7 Analysts Have This to Say About Cabaletta Bio
See More Headlines
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CABA
Fax
N/A
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.64
High Stock Price Target
$50.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+70.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-52,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.60 per share

Miscellaneous

Free Float
37,566,000
Market Cap
$695.44 million
Optionable
Not Optionable
Beta
2.42
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Steven A. Nichtberger M.D. (Age 62)
    Co-Founder, Chairman, CEO & President
    Comp: $970.6k
  • Dr. Gwendolyn K. Binder Ph.D. (Age 48)
    President of Science & Technology
    Comp: $692.99k
  • Dr. David J. Chang FACR (Age 60)
    M.D., M.P.H., Chief Medical Officer
    Comp: $676.74k
  • Dr. Michael C. Milone M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Dr. Aimee Payne M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Mr. Anup Marda M.B.A. (Age 46)
    Chief Financial Officer
    Comp: $548.2k
  • Dr. Samik Basu M.D.
    Chief Scientific Officer
  • Mr. Michael Gerard J.D. (Age 43)
    General Counsel & Secretary
  • Ms. Heather Harte-Hall M.Sc.
    Chief Compliance Officer
  • Ms. Martha O'Connor
    Chief Human Resources Officer














CABA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares.
View CABA analyst ratings
or view top-rated stocks.

What is Cabaletta Bio's stock price target for 2024?

10 analysts have issued 1-year price targets for Cabaletta Bio's stock. Their CABA share price targets range from $10.00 to $50.00. On average, they predict the company's stock price to reach $27.64 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price.
View analysts price targets for CABA
or view top-rated stocks among Wall Street analysts.

How have CABA shares performed in 2023?

Cabaletta Bio's stock was trading at $9.25 at the beginning of the year. Since then, CABA stock has increased by 75.5% and is now trading at $16.23.
View the best growth stocks for 2023 here
.

Are investors shorting Cabaletta Bio?

Cabaletta Bio saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 5,060,000 shares, a drop of 19.4% from the October 31st total of 6,280,000 shares. Based on an average trading volume of 788,600 shares, the days-to-cover ratio is currently 6.4 days.
View Cabaletta Bio's Short Interest
.

When is Cabaletta Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CABA earnings forecast
.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) announced its earnings results on Thursday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02.

What ETFs hold Cabaletta Bio's stock?

ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO.

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Fred Alger Management LLC (9.94%), Lynx1 Capital Management LP (4.91%), Redmile Group LLC (4.14%), Jennison Associates LLC (3.57%), Invesco Ltd. (1.99%) and Northern Trust Corp (0.70%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am.
View institutional ownership trends
.

How do I buy shares of Cabaletta Bio?

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CABA) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -